Blab Business
Pfizer Faces Revenue Decline and Patent Cliffs, but New Deals and Acquisitions Offer a Path Forward
Pfizer Inc. reported a 1.6% drop in 2025 revenue to $62.6 billion, a sharp decline from the $100 billion peak reached in 2022 when the company’s COVID‑19 vaccine and antiviral sales were at their highest. The fall reflects a broader easing of demand for the company’s pandemic‑era products and the looming expiration of several blockbuster drugs.
The pandemic‑era surge was driven largely by the Comirnaty vaccine and Paxlovid antiviral, both of which have seen sales taper off as global immunity grows and new treatments emerge. In 2025, the company’s top‑selling products—Eliquis (apixaban), Prevnar 13, Paxlovid, Vyndaqel, Comirnaty, and Ibrance—generated $62.6 billion in total revenue, with Eliquis alone accounting for $7.9 billion.
A key risk for Pfizer is the impending loss of patent protection on three of its most profitable drugs—Eliquis, Ibrance, and Xtandi—next year. The company estimates that these three drugs together contributed more than $20 billion to 2025 revenue. Prevnar 13, a pneumococcal vaccine, is also approaching its patent expiry. The loss of exclusivity is expected to open the market to generic competitors, potentially eroding Pfizer’s margin and cash flow.
To counteract the impact of patent cliffs, Pfizer has pursued an aggressive acquisition strategy. In November 2025, the company completed a $10 billion purchase of Metsera, adding a pipeline of anti‑obesity candidates. Earlier, Pfizer acquired Seagen for $43 billion, bringing a suite of antibody‑drug conjugate oncology drugs into its portfolio. In 2022, the company also bought Global Blood Therapeutics, Biohaven Pharmaceutical Holding, and ReViral, all aimed at replenishing its pipeline and diversifying revenue streams.
A recent partnership with China‑based Innovent Biologics is another step toward stabilizing the company’s income base. The deal, announced in early 2026, is expected to provide Pfizer with access to Innovent’s oncology assets and a foothold in the Chinese market, where Pfizer’s revenue share is only about 5 percent. Analysts view the collaboration as a potential model for future international deals that could help offset the revenue loss from patent expirations.
During the first‑quarter earnings call, CEO Albert Bourla highlighted a settlement agreement that resolves a patent dispute over Vyndamax, a drug used to treat transthyretin‑mediated amyloid cardiomyopathy. Bourla said the settlement could change Pfizer’s growth profile after 2028 and gave the company confidence that, beginning in 2029, it could enter a five‑year period of high‑single‑digit compound annual growth. The company plans to launch roughly 20 pivotal clinical trials in 2026, many of which are tied to the new acquisitions and partnerships.
Investor sentiment has been mixed. Shares have fallen in line with concerns that the company may struggle to maintain its dividend in the face of shrinking blockbuster sales. The partnership with Innovent and the pipeline expansion are viewed as mitigating factors, but analysts caution that the timing of patent expirations and the performance of new drugs will ultimately determine whether Pfizer can sustain its dividend.
Looking ahead, Pfizer’s next earnings report will provide further insight into the performance of its new acquisitions and the progress of its clinical trials. The company’s board will also review its dividend policy in light of the evolving revenue landscape. Regulatory developments, particularly in China, could influence the success of the Innovent partnership, while the broader generic drug market will shape the impact of the upcoming patent expirations.
In summary, Pfizer’s 2025 revenue decline underscores the challenges of a post‑pandemic market and the threat of patent cliffs. The company’s acquisition spree and new partnership with Innovent Biologics are strategic moves aimed at replenishing its pipeline and diversifying its revenue base. Investors will be watching the company’s quarterly results, dividend decisions, and the performance of its newly acquired assets to gauge whether Pfizer can navigate the transition and sustain growth in the coming years.
The pandemic‑era surge was driven largely by the Comirnaty vaccine and Paxlovid antiviral, both of which have seen sales taper off as global immunity grows and new treatments emerge. In 2025, the company’s top‑selling products—Eliquis (apixaban), Prevnar 13, Paxlovid, Vyndaqel, Comirnaty, and Ibrance—generated $62.6 billion in total revenue, with Eliquis alone accounting for $7.9 billion.
A key risk for Pfizer is the impending loss of patent protection on three of its most profitable drugs—Eliquis, Ibrance, and Xtandi—next year. The company estimates that these three drugs together contributed more than $20 billion to 2025 revenue. Prevnar 13, a pneumococcal vaccine, is also approaching its patent expiry. The loss of exclusivity is expected to open the market to generic competitors, potentially eroding Pfizer’s margin and cash flow.
To counteract the impact of patent cliffs, Pfizer has pursued an aggressive acquisition strategy. In November 2025, the company completed a $10 billion purchase of Metsera, adding a pipeline of anti‑obesity candidates. Earlier, Pfizer acquired Seagen for $43 billion, bringing a suite of antibody‑drug conjugate oncology drugs into its portfolio. In 2022, the company also bought Global Blood Therapeutics, Biohaven Pharmaceutical Holding, and ReViral, all aimed at replenishing its pipeline and diversifying revenue streams.
A recent partnership with China‑based Innovent Biologics is another step toward stabilizing the company’s income base. The deal, announced in early 2026, is expected to provide Pfizer with access to Innovent’s oncology assets and a foothold in the Chinese market, where Pfizer’s revenue share is only about 5 percent. Analysts view the collaboration as a potential model for future international deals that could help offset the revenue loss from patent expirations.
During the first‑quarter earnings call, CEO Albert Bourla highlighted a settlement agreement that resolves a patent dispute over Vyndamax, a drug used to treat transthyretin‑mediated amyloid cardiomyopathy. Bourla said the settlement could change Pfizer’s growth profile after 2028 and gave the company confidence that, beginning in 2029, it could enter a five‑year period of high‑single‑digit compound annual growth. The company plans to launch roughly 20 pivotal clinical trials in 2026, many of which are tied to the new acquisitions and partnerships.
Investor sentiment has been mixed. Shares have fallen in line with concerns that the company may struggle to maintain its dividend in the face of shrinking blockbuster sales. The partnership with Innovent and the pipeline expansion are viewed as mitigating factors, but analysts caution that the timing of patent expirations and the performance of new drugs will ultimately determine whether Pfizer can sustain its dividend.
Looking ahead, Pfizer’s next earnings report will provide further insight into the performance of its new acquisitions and the progress of its clinical trials. The company’s board will also review its dividend policy in light of the evolving revenue landscape. Regulatory developments, particularly in China, could influence the success of the Innovent partnership, while the broader generic drug market will shape the impact of the upcoming patent expirations.
In summary, Pfizer’s 2025 revenue decline underscores the challenges of a post‑pandemic market and the threat of patent cliffs. The company’s acquisition spree and new partnership with Innovent Biologics are strategic moves aimed at replenishing its pipeline and diversifying its revenue base. Investors will be watching the company’s quarterly results, dividend decisions, and the performance of its newly acquired assets to gauge whether Pfizer can navigate the transition and sustain growth in the coming years.
